Internal restructuring
Hessen; Darmstadt; Frankfurt am Main
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

400 jobs
Number of planned job losses
Job loss
Announcement Date
22 November 2017
Employment effect (start)
1 July 2018
Foreseen end date
31 December 2020


As announced on 22 November 2017, the German pharmaceutical company Sanofi-Aventis will be cutting 400 jobs until the end of 2020 due to internal restructuring. Sanofi-Aventis will not extend 250 temporary contracts and will be offering early retirement packages as well as severance packages to an additional 150 permanent employees. Affected employees are mainly working in the production of medication for diabetic patients. The production of the long-term-insulin Lantus has plummeted in the last 2 years due to expiry of its patent. As a result, management deems job reductions inevitable in order to preserve the company's competitiveness.

Management and works council will start negotiations regarding a social plan next week.

Previously, in March 2017, Sanofi-Aventis also announced a reduction of 480 jobs in the production department. 


  • 22 November 2017: FAZ Online
  • 23 November 2017: FAZ (E-Paper)


Eurofound (2017), Sanofi-Aventis, Internal restructuring in Germany, factsheet number 92618, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/92618.